Q-omics provides the consensus-scored KLF2P4 profile across patient tissues and cancer cell-line models. KLF2P4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KLF2P4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, KLF2P4 RNA expression shows 11,681 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, THCA, and THYM as cancer lineages where KLF2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF2P4 survival associations across molecular data types. KLF2P4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF2P4 RNA expression–survival associations across cancer types. High KLF2P4 expression shows unfavorable associations in LUAD, LGG, DLBC, ACC, COAD and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KLF2P4 RNA expression.
This table summarizes KLF2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KLF2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF2P4 shows lower tumor expression in THCA and KIRC and higher tumor expression in STAD, UCEC, HNSC and LUSC. The THCA box plot shows higher KLF2P4 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p = .002).
This table shows molecular features associated with KLF2P4 in patient tissues and cancer cell lines. In patient samples, KLF2P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
